Entry: $21.88 (2026-03-20) | Current: $28.39 | Gain: +29.7% (+$1,070.93 notional) --- 1. IS THE ORIGINAL THESIS STILL INTACT? The Short Answer: Technically yes. Fundamentally... it's complicated. The data doesn't lie, and right now it's telling an uncomfortable story: - INGM's assets declined modestly: $21,244M (2025-12) → $20,946M (2026-03) - EPS deteriorated sharply: $1.39 (2025-12) → $0.42 (2026-03) — that's a 70% sequential collapse Here's what I've been wrestling with all week: the operational thesis — FCF generation, declining debt, rising ROIC — was never validated in real-time. I built a position on *expected* quality improvements that simply haven't shown up in the earnings data. What the original thesis claimed: - Consistent free cash flow generation ✗ (unverifiable without cash flow statements) - Declining debt levels ✗ (asset base is shrinking, but the debt picture remains murky) - Rising ROIC ✗ (EPS compression points to margin pressure, not expansion) What still holds: Ingram is a distribution play in a cyclically-resilient sector. That structural moat hasn't disappeared. What doesn't: A 70% Q1 2026 EPS collapse signals one of three things: 1. One-time charges (possible — needs 10-Q detail) 2. Structural margin compression in the distribution channel 3. Revenue contraction driving working capital pressure I can't distinguish between them without granular filing data. That's not a minor gap — that's a core problem. --- 2. WHAT HAS SURPRISED ME ABOUT THIS POSITION'S PERFORMANCE? The surprise here isn't pleasant. It's a glaring mismatch between conviction and reality. | What I Expected | What Actually Happened | Surprise Factor | |---|---|---| | Steady earnings growth | 70% EPS collapse Q1 2026 | Severe | | Valuation compression benefit as rates fell | Rates *didn't* fall; 10Y held at 4.46% | Moderate | | Distribution margin stability in "higher-for-longer" regime | EPS data suggests compression | Severe | | Conviction maintenance on fundamentals | Conviction dropped 7→5/10 | Self-inflicted | The real surprise: The stock is up 29.7% *despite* deteriorating near-term earnings. The market is either: - Pricing in a cyclical recovery that hasn't shown up in the data yet - Ignoring the EPS print entirely - Rotating into "beaten-down" distribution plays and betting on multiple expansion None of those are bullish signals. They're fragility signals. A stock that rises on bad fundamentals is a stock

Research these companies